The discovery of an enzyme that stops and reverse the deadly liver fibrosis

According to RCO News AgencyLiver fibrosis often develops without symptoms and has no approved treatment, but researchers at the University of Sunderland have discovered a new enzyme blocker treatment that can ultimately help stop or reverse the disease.

Fibrosis, or “fiber corruption”, is the disease of the swelling of the filamentous tissue, and the hardening of connective tissue, which results in the increase in the formation of fibers in the connective tissue during a recovery or irreversible process. Fibrosis may be benign, malignant or pathogenic.

According to IA, Dr. Maria Teresa Borrelo and his team found that blocking an enzyme called “HDAC1” with new developed drugs could reduce liver ulcers in people with fibrosis.

The “HDAC1” enzyme is involved in regulating inflammation and cellular stress, and research shows that the activation of liver star cells responsible for collagen production (the main tissue stimulant).

Blocking damage in source

Dr. Borllo, a lecturer in pharmaceutical chemistry at the University of Sunderland, said his team has developed two new drugs designed specifically to prevent HDAC1 activity.

“We have so far seen a encouraging laboratory that shows that inhibitors or” HDAC1 “inhibitors or blockers are reducing inflammation and cellular stress responses, both of which are key fibrosis factors,” he said.

“The findings support the idea that” HDAC1 “is a promising drug goal for the treatment of liver fibrosis,” he said. We have also begun to understand more about how these compounds work at the molecular level, which is essential to designing better and safer treatments.

The researchers hope that their findings will be the basis for new treatments that can significantly improve the lives of people with the disease and other inflammatory diseases, including skin disorders.

“The study is a step forward in finding a treatment for” liver fibrosis “,” says Dr. Borlo. Our HDAC3 inhibitors provide a more targeted approach, and by focusing on a main cause of the fibrosis, we may be able to stop the disease before reaching irreversible stages.

By stopping or reverseing this process, we can reduce the need for liver transplantation and improve long -term health results.

From the laboratory to the liver

Researchers believe that targeting the main cause of fibrosis can be a turning point in the treatment of liver disease.

As efforts to counter chronic conditions, such accurate treatments can change how to manage untreatable diseases.

The British Liver Liver Charity has welcomed the findings of the study.

“Liver disease is often without symptoms, and most people only realize that it is too late for effective treatment,” says Pamela Healy. While this new study is still in its early stages, it is a promise of therapeutic development that can improve and save the lives of thousands of liver disease.

Liver disease is responsible for about four percent of the world’s premature deaths, with “liver fibrosis” one of the most serious and often unknown forms.

In the United Kingdom only, about 5 million people have the disease. This condition occurs when prolonged damage to the liver, which is usually caused by alcohol, obesity, or chronic infections, causes tissue to form.

As the wound worsen over time, it can lead to life -threatening complications such as liver failure or cancer.

Since its symptoms often appear only in advanced stages, many people are unaware of the disease, and there are currently no approved treatment to stop or reverse this process.

This study is published in The FBS journal.

The end of the message